Wall Street’s major market averages seesawed back and forth on Friday and finished mixed as Federal Reserve Governor ...

WASHINGTON (AP) — Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in ...

Fintel reports that on June 20, 2025, William Blair downgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...

The death of a boy with Duchenne muscular dystrophy, tied to a gene therapy, is above all a tragedy. But it is also ...

Sarepta shares face pressure after a second Elevidys-linked death and analyst downgrade over safety concerns and lowered revenue prospects.

Duchenne muscular dystrophy families are sharing stories about Elevidys complications on social media. But they aren’t ...

Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.

The Alliance for Regenerative Medicine has voiced deep disappointment about reports that the FDA has put the director of its ...

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic ...

Ticker: Second patient death reported with gene therapy for muscular dystrophy; Salmonella poisoning linked to pistachio ...

The biotech industry faces a mix of longstanding and novel political challenges amid President Donald Trump’s second term.